ArticleAnnals of surgical oncology2026
Investigating Age-Related Differences in Survival Outcomes and Mutation Status of Patients with Intrahepatic Cholangiocarcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSurvival outcomes for intrahepatic cholangiocarcinoma (IHC) remain poor due to late-stage presentation and limited effective treatment options. Previous studies have suggested age-related differences in outcome, but the results are mixed, and there is substantial variation in the definition of "young."
methodsA retrospective review analyzed 938 consecutive patients with a diagnosis of IHC between 2000 and 2018 at a single institution. Risk factors for IHC, clinical characteristics at diagnosis, and genomics were assessed for potential differences at the extremes of age (≤50 vs ≥70 years).
resultsThe final cohort (n = 430) included 142 patients 50 years or younger and 288 patients older than 70. The most common genetic alterations were IDH1mut (22%), p53mut (17%), KRASmut (9.8%), and FGFR2fus (6.3%). Young patients had a higher proportion of FGFR2fus (p = 0.020). The median overall survival (OS) for the entire cohort was 23 months (95% confidence interval [CI], 20-27 months). In the resected group, recurrence-free survival (RFS) was longer for the older patients (median 27 vs 17months), but OS did not differ significantly (23 vs 25 months; p = 0.3). By contrast, among the unresectable patients, OS was significantly better for the younger patients (p = 0.008), but no significant relationship was observed between age and resection status when OS was assessed (p = 0.7).
conclusionGenomic differences between older and younger patients did not appear to drive the differences in OS observed in this cohort. Intrahepatic cholangiocarcinoma patients 50 years or younger likely do not represent a distinct subgroup despite differences in presentation and clinical characteristics.
Indexed as
Identifiers
42426481What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.